EFFECTOR THERAPEUTICS INC (EFTR) Stock Price, Forecast & Analysis
USA - NASDAQ:EFTR - US28202V2079 - Common Stock
EFTR Key Statistics, Chart & Performance
The current stock price of EFTR is 0.18 USD. In the past month the price decreased by -88.46%. In the past year, price decreased by -99.13%.
EFTR Latest News, Press Relases and Analysis
EFTR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About EFTR
Company Profile
eFFECTOR Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Solana Beach, California and currently employs 15 full-time employees. The company went IPO on 2021-01-08. eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Company Info
EFFECTOR THERAPEUTICS INC
142 North Cedros Avenue, Suite B, Suite A
Solana Beach CALIFORNIA US
CEO: John M. Butler
Employees: 15
Phone: 18589258215
EFFECTOR THERAPEUTICS INC / EFTR FAQ
What does EFTR do?
eFFECTOR Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Solana Beach, California and currently employs 15 full-time employees. The company went IPO on 2021-01-08. eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Can you provide the latest stock price for EFFECTOR THERAPEUTICS INC?
The current stock price of EFTR is 0.18 USD. The price decreased by -32.56% in the last trading session.
Does EFTR stock pay dividends?
EFTR does not pay a dividend.
How is the ChartMill rating for EFFECTOR THERAPEUTICS INC?
EFTR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of EFFECTOR THERAPEUTICS INC (EFTR)?
EFFECTOR THERAPEUTICS INC (EFTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.08).
What is EFFECTOR THERAPEUTICS INC worth?
EFFECTOR THERAPEUTICS INC (EFTR) has a market capitalization of 846.00K USD. This makes EFTR a Nano Cap stock.
EFTR Technical Analysis
EFTR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EFTR. The financial health of EFTR is average, but there are quite some concerns on its profitability.
EFTR Financial Highlights
Over the last trailing twelve months EFTR reported a non-GAAP Earnings per Share(EPS) of -13.08. The EPS decreased by -9.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.64% | ||
| ROE | -4187.55% | ||
| Debt/Equity | 0 |
EFTR Forecast & Estimates
8 analysts have analysed EFTR and the average price target is 11.22 USD. This implies a price increase of 6133.33% is expected in the next year compared to the current price of 0.18.